Patrick Cournoyer News Today

U.S. Senator Tommy Tuberville (R-Montgomery) is not happy and he is about to turn this government around if lawmakers don't knock off all of this "organized grabass"

On April 11, at an industry conference in Colorado, FDA’s Patrick Cournoyer discussed a pathway forward for CBD and explained why existing pathways are not appropriate.

The 10th annual NoCo Hemp Expo is underway in Estes Park, Colorado, where industry stakeholders are gathering to collaborate, commiserate and celebrate the state of hemp in 2024.

The cannabis sector is excited for several major catalysts that could help provide momentum after setbacks.

The Food and Drug Administration (FDA) is pushing for greater authority over hemp-derived cannabinoid products, signaling a possible shift in the cannabis industry's regulatory landscape.

Lawmakers on Capitol Hill are hearing starkly different messages from FDA and hemp industry stakeholders on the safety profile of cannabidiol (CBD).

Dietary supplement trade groups contend a "harm-reduction” framework for CBD envisioned by FDA would undermine the law applicable to the commodity.

With the ongoing theme of safety, FDA recently addressed CBD. While offering up several potential scenarios, the Agency said the CBD marketplace ultimately rests in the hands of Congress.

An FDA official last week reiterated concerns over the potential risks of synthetic cannabinoids, including delta-8 THC.

FDA envisions a pathway for CBD in food and dietary supplements that reduces harm while helping consumers make informed decisions regarding their health.